Friday 27 June 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Janssen/Cilag Link

Janssen/Cilag Link

9 January 1995

Effective January 1, Johnson & Johnson's UK subsidiaries Janssen Pharmaceutical Ltd and Cilag Ltd have become Janssen-Cilag Ltd, as part of a realignment of the group's pharmaceutical business in the UK. The new company's address is Saunderton, High Wycombe, Bucks HP14 4HY. Phone: +44 1494 567567; fax: +44 1494 576568.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Calico signs $571 million licensing deal with Mabwell for IL-11 drug
Biotechnology
Calico signs $571 million licensing deal with Mabwell for IL-11 drug
27 June 2025
Pharmaceutical
Bayer extends long-standing Tsinghua University partnership
27 June 2025
Biosimilars
Formycon increases bond volume following oversubscription
27 June 2025
Biotechnology
New data for nusinersen underscore Biogen’s commitment to SMA
27 June 2025
Pharmaceutical
CDC’s ACIP meets, stressing ‘no pre-determined ideas’
27 June 2025
Biotechnology
BeOne Medicines showcases oncology pipeline
27 June 2025
Biotechnology
Philogen withdraws MAA for Nidlegy in EU
27 June 2025

Company Spotlight

A data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze